Salmon calcitonin (Miacalcic) nasal spray in prevention and treatment of XXXX .

@entity172 @entity1 @entity175 @entity137 @entity174 @entity170 @entity460 @entity158
@entity175 (CT) constitutes one of the major choices for the pharmacologic treatment of postmenopausal and @entity170 . In @entity170 , CT, analogous to @entity172 , determines increase of bone mass, improvement of intestinal @entity460 absorption and a positivization of @entity460 balance. @entity1 treated with CT can also benefit from the analgesic effect of the hormone. Unlike @entity172 , these beneficial effects of CT occur with minimal risk and require no routine gynecological monitoring. In addition, CT is completely devoid of @entity137 . The only limitations to the use of CT are linked to the frequent parenteral injections and the occurrence of side effects. These limitations can now be overcome by the availability of the new nasal spray preparation, which has been developed for synthetic salmon calcitonin (sCT). The introduction of this new form increases the @entity1 ' compliance, and the different pharmacokinetic curtails the side effects, compared to the parenteral administration. At present, one-year controlled studies have been reported, showing a beneficial effect of sCT on bone mass in @entity1 with established @entity170 . Also, shorter studies demonstrate the analgesic activity of sCT treatment in @entity1 with @entity174 and @entity158 . The improvement in the @entity1 ' compliance and the reduction of side effects allow this new CT preparation to be used in the prevention of @entity170 .
